Up next

DCAT Value Chain Insights Bonus Coverage: From DCAT Week 2024: Supplier News Roundup 

What other DCAT Member Companies are making the news? A roundup of the latest developments from CDMOs/CMOs and other suppliers in drug-substance (small molecules & biologics) and drug-product development and manufacturing and packaging.

What other DCAT Member Companies are making the news? A roundup of the latest developments from CDMOs/CMOs and other suppliers in drug-substance (small molecules & biologics) and drug-product development and manufacturing and packaging. 

Companies making the news 
Here is a roundup of recent news announcements from DCAT Member Companies across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms), and packaging.  
 
See related stories and the companies making the news below:   

From DCAT Week 2024: Supplier News: Chemicals/Chemical API Manufacturing
Featuring news from Olon, Grace, PharmaBlock, Axplora, ChemCon, Suven Pharma and The Solubility Company. 

From DCAT Week 2024: Supplier News: Biologics Manufacturing
Featuring news from Siegfried and Solvias. 

From DCAT Week 2024: Supplier News: Formulation Development/Drug Product Manufacturing 
Featuring news from Alcami, Corealis Pharma, Curia, Delpharm and Grand River Aseptic Manufacturing. 

From DCAT Week 2024: Supplier News: End-to-End (Drug Substance and Drug Product)
Featuring news from Lonza and Mabion.  

From DCAT Week 2024: Supplier News: Packaging 
Featuring news from Adare Pharma Solutions and ApiJect 

Recent Feature Articles

Will New Oral GLP-1 Agonists Be the Next Market Shaker?

By
The blockbuster success of Novo Nordisk’s Ozempic/Wegovy and Lilly’s Mounjaro/Zepbound, all injectables, have put GLP-1/GIP agonists on the map, but will new oral drugs be a game-changer?

The Push To Onshore US Pharma Manufacturing: What’s on the Table?

By
Congress is moving forward with proposed legislation to increase both new and reshored pharma manufacturing in the US. What measures are being considered, and where do they stand?

On the Rise: CDMO/CMO Expansions for Injectables

By
Strong growth is projected for the injectables drugs market, and CDMOs/CMOS are expanding sterile manufacturing & fill–finish capacity. Which companies are expanding and who is leading the charge?

Pharma Industry-Specific Tariffs: Industry Weighs In

By
The industry has weighed in on the US government’s potential plan to impose tariffs specific to the pharmaceutical industry. Where does the initiative stand, and what is the industry saying?